© 2023 MJH Life Sciences and Urology Times. All rights reserved.
© 2023 MJH Life Sciences™ and Urology Times. All rights reserved.
June 13, 2022
The ENZAMET study explored enzalutamide in patients with metastatic hormone-sensitive prostate cancer.
June 10, 2022
Lead author Ian Davis, MBBS, PhD, discusses the results of the ENZAMET study update he shared during the 2022 ASCO Annual Meeting.
June 09, 2022
Combining radiotherapy with next-generation hormonal therapy is a feasible approach to explore in phase 3 trials enrolling patients with high-risk localized or locally advanced prostate cancer, according to an analysis of the phase 3 ATLAS trial.
“I think immunotherapy in the neoadjuvant and also in the BCG-unresponsive setting are here to stay,” says Roger Li, MD.
June 08, 2022
Overall survival was higher among patients with mHSPC who achieved undetectable PSA levels when treated with the triplet of darolutamide, ADT, and docetaxel, according to an analysis from the phase 3 ARASENS trial.
June 07, 2022
The median time between PSA progression and metastasis was 7.0 months for darolutamide compared with 5.6 months for placebo.
June 06, 2022
The biomarker analysis used next-generation sequencing to analyze ctDNA and genomic aberrations in 17 prostate cancer–related genes at baseline and at end of study treatment.
“Darolutamide, unlike enzalutamide, does not affect cabazitaxel systemic exposure, justifying their use in combination,” the authors wrote in their poster.
“We found in ARCHES that in the men who developed radiographic progression while on ADT-enzalutamide [Xtandi], two thirds of these patients, when they had radiographic progression, did not meet PSA progression criteria, and one third didn't have any rise at all in their PSA,” says Andrew J. Armstrong, MD, MSc.
Based on the efficacy of the LITESPARK-001 study, the phase 3 LITESPARK-005 study of belzutifan has already been launched, says Eric Jonasch, MD.